Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Human Genome Sciences Inc (HGSI) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Human Genome Sciences Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 901219.
Total stock buying since 2010: $1,152,555,528.
Total stock sales since 2010: $14,425,410.
Total stock option exercises since 2010: $5,356,908.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2012 | 80,742,545 | $1,150,581,263 | 0 | $0 | 176,474 | $1,244,175 |
| 2011 | 88,226 | $1,958,534 | 194,112 | $5,677,266 | 213,557 | $1,431,071 |
| 2010 | 801 | $15,731 | 325,727 | $8,748,144 | 346,210 | $2,681,662 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2012-08 | 75,807,802 | $1,080,261,176 | 0 | $0 | 0 | $0 |
| 2012-07 | 4,934,743 | $70,320,087 | 0 | $0 | 176,474 | $1,244,175 |
| 2011-08 | 23,000 | $366,410 | 0 | $0 | 12,009 | $25,098 |
| 2011-07 | 0 | $0 | 0 | $0 | 18,362 | $156,995 |
| 2011-06 | 0 | $0 | 22,904 | $620,950 | 22,904 | $287,674 |
| 2011-05 | 0 | $0 | 16,000 | $480,000 | 16,000 | $40,646 |
| 2011-04 | 0 | $0 | 147,282 | $4,360,024 | 144,282 | $920,658 |
| 2011-03 | 5,226 | $142,524 | 7,926 | $216,292 | 0 | $0 |
| 2011-01 | 60,000 | $1,449,600 | 0 | $0 | 0 | $0 |
| 2010-10 | 0 | $0 | 22,903 | $682,394 | 22,903 | $287,661 |
| 2010-09 | 0 | $0 | 76,000 | $2,281,034 | 76,000 | $489,126 |
| 2010-08 | 0 | $0 | 73,590 | $2,075,728 | 73,590 | $566,962 |
| 2010-07 | 801 | $15,731 | 21,871 | $591,523 | 24,701 | $17,286 |
| 2010-06 | 0 | $0 | 131,363 | $3,117,465 | 149,016 | $1,320,627 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2012-08-02 | Glaxosmithkline Plc (Director) | Buy | 62,646,186 | 14.25 | 892,708,150 |
| 2012-08-01 | Glaxosmithkline Plc (Director) | Buy | 7,474,901 | 14.25 | 106,517,338 |
| 2012-07-30 | Glaxosmithkline Plc (Director) | Buy | 4,934,743 | 14.25 | 70,320,087 |
| 2012-07-25 | Labinger Barry (Exec VP & CCO) | Option Ex | 31,480 | 2.72 | 85,625 |
| 2012-07-24 | Stump David C (Exec. Vice President) | Option Ex | 68,701 | 7.26 | 498,769 |
| 2012-07-23 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Option Ex | 76,293 | 8.65 | 659,781 |
| 2011-08-10 | Lamattina John L (Director) | Option Ex | 12,009 | 2.09 | 25,098 |
| 2011-08-05 | Ha Ngoc Tuan (Director) | Buy | 10,000 | 16.00 | 160,000 |
| 2011-08-05 | Morrow George J (Director) | Buy | 10,000 | 15.79 | 157,900 |
| 2011-08-04 | Goddard Colin (Director) | Buy | 3,000 | 16.17 | 48,510 |
| 2011-07-26 | Labinger Barry (Exec VP & CCO) | Option Ex | 18,362 | 8.55 | 156,995 |
| 2011-06-01 | Simpson Curran (Sr. VP, Operations) | Sale | 22,904 | 27.11 | 620,950 |
| 2011-06-01 | Simpson Curran (Sr. VP, Operations) | Option Ex | 22,904 | 12.56 | 287,674 |
| 2011-05-02 | Labinger Barry (Exec VP & CCO) | Sale | 7,347 | 30.00 | 220,410 |
| 2011-05-02 | Labinger Barry (Exec VP & CCO) | Option Ex | 7,347 | 4.92 | 36,147 |
| 2011-05-02 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Sale | 8,653 | 30.00 | 259,590 |
| 2011-05-02 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Option Ex | 8,653 | .52 | 4,499 |
| 2011-04-29 | Simpson Curran (Sr. VP, Operations) | Sale | 28,015 | 28.98 | 812,014 |
| 2011-04-29 | Simpson Curran (Sr. VP, Operations) | Option Ex | 28,015 | 11.08 | 310,406 |
| 2011-04-28 | Labinger Barry (Exec VP & CCO) | Sale | 39,966 | 30.00 | 1,198,980 |
| 2011-04-28 | Labinger Barry (Exec VP & CCO) | Option Ex | 39,966 | 2.72 | 108,707 |
| 2011-04-28 | Bateson Susan D. (Senior Vice President) | Sale | 3,000 | 30.00 | 90,000 |
| 2011-04-20 | Bateson Susan D. (Senior Vice President) | Sale | 24,000 | 28.75 | 690,000 |
| 2011-04-20 | Bateson Susan D. (Senior Vice President) | Option Ex | 24,000 | .52 | 12,480 |
| 2011-04-14 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Sale | 31,401 | 30.00 | 942,030 |
| 2011-04-14 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Option Ex | 31,401 | 9.35 | 293,630 |
| 2011-04-13 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Sale | 20,900 | 30.00 | 627,000 |
| 2011-04-13 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Option Ex | 20,900 | 9.35 | 195,435 |
| 2011-03-22 | Goddard Colin (Director) | Buy | 2,726 | 27.41 | 74,727 |
| 2011-03-21 | Gowen Maxine (Director) | Sale | 7,926 | 27.29 | 216,292 |
| 2011-03-18 | Norden Gregory (Director) | Buy | 2,500 | 27.12 | 67,797 |
| 2011-01-05 | Watkins Thomas (Chief Executive Officer) | Buy | 60,000 | 24.16 | 1,449,600 |
| 2010-10-01 | Simpson Curran (Sr. VP, Operations) | Sale | 22,903 | 29.80 | 682,394 |
| 2010-10-01 | Simpson Curran (Sr. VP, Operations) | Option Ex | 22,903 | 12.56 | 287,661 |
| 2010-09-20 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Sale | 26,000 | 30.01 | 780,234 |
| 2010-09-20 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Option Ex | 26,000 | 9.35 | 243,126 |
| 2010-09-01 | Labinger Barry (Exec VP & CCO) | Sale | 50,000 | 30.02 | 1,500,800 |
| 2010-09-01 | Labinger Barry (Exec VP & CCO) | Option Ex | 50,000 | 4.92 | 246,000 |
| 2010-08-27 | Labinger Barry (Exec VP & CCO) | Sale | 16,079 | 28.50 | 458,283 |
| 2010-08-27 | Labinger Barry (Exec VP & CCO) | Option Ex | 16,079 | 4.92 | 79,108 |
| 2010-08-26 | Labinger Barry (Exec VP & CCO) | Sale | 13,050 | 28.53 | 372,355 |
| 2010-08-26 | Labinger Barry (Exec VP & CCO) | Option Ex | 13,050 | 4.92 | 64,206 |
| 2010-08-25 | Simpson Curran (Sr. VP, Operations) | Sale | 18,461 | 28.00 | 516,908 |
| 2010-08-25 | Simpson Curran (Sr. VP, Operations) | Option Ex | 18,461 | 9.78 | 180,548 |
| 2010-08-25 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Sale | 26,000 | 28.01 | 728,182 |
| 2010-08-25 | Davis James H (Exec. VP, Gen Counsel & Sec.) | Option Ex | 26,000 | 9.35 | 243,100 |
| 2010-07-26 | Labinger Barry (Exec VP & CCO) | Sale | 21,871 | 27.05 | 591,523 |
| 2010-07-26 | Labinger Barry (Exec VP & CCO) | Option Ex | 21,871 | .52 | 11,372 |
| 2010-07-23 | Young Robert C (Director) | Option Ex | 2,830 | 2.09 | 5,914 |
| 2010-07-12 | Watkins Thomas (Chief Executive Officer) | Buy | 801 | 19.64 | 15,731 |
| 2010-06-30 | Drews Jurgen (Director) | Sale | 37,634 | 23.36 | 879,318 |
| 2010-06-30 | Drews Jurgen (Director) | Option Ex | 37,634 | 6.25 | 235,212 |
| 2010-06-29 | Drews Jurgen (Director) | Sale | 37,634 | 22.84 | 859,410 |
| 2010-06-29 | Drews Jurgen (Director) | Option Ex | 37,634 | 10.70 | 402,495 |
| 2010-06-28 | Drews Jurgen (Director) | Sale | 37,634 | 23.85 | 897,533 |
| 2010-06-28 | Drews Jurgen (Director) | Option Ex | 37,634 | 11.22 | 422,140 |
| 2010-06-11 | Simpson Curran (Sr. VP, Operations) | Sale | 18,461 | 26.07 | 481,204 |
| 2010-06-11 | Simpson Curran (Sr. VP, Operations) | Option Ex | 18,461 | 9.78 | 180,548 |
| 2010-06-01 | Southwell David P (David Southwell) | Option Ex | 17,653 | 4.54 | 80,232 |
Insider trading activities including stock purchases, stock sales, and option exercises of HGSI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Human Genome Sciences Inc (symbol HGSI, CIK number 901219) see the Securities and Exchange Commission (SEC) website.